Witnessing the stock’s movement on the chart, on Thursday, Immuneering Corp (NASDAQ: IMRX) had a quiet start as it plunged -10.06% to $5.54, before settling in for the price of $6.16 at the close. Taking a more long-term approach, IMRX posted a 52-week range of $1.10-$10.08.
The Healthcare sector firm’s twelve-monthly sales growth has been -46.45% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -46.45%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 21.47%. This publicly-traded company’s shares outstanding now amounts to $60.53 million, simultaneously with a float of $36.18 million. The organization now has a market capitalization sitting at $335.34 million. At the time of writing, stock’s 50-day Moving Average stood at $6.09, while the 200-day Moving Average is $3.13.
Immuneering Corp (IMRX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Immuneering Corp’s current insider ownership accounts for 40.22%, in contrast to 6.37% institutional ownership. According to the most recent insider trade that took place on Oct 03 ’25, this organization’s Director bought 7,500 shares at the rate of 6.67, making the entire transaction reach 50,025 in total value, affecting insider ownership by 156,766. Preceding that transaction, on Oct 01 ’25, Company’s Chief Accounting Officer bought 300 for 6.39, making the whole transaction’s value amount to 1,917. This particular insider is now the holder of 27,533 in total.
Immuneering Corp (IMRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
Immuneering Corp’s EPS increase for this current 12-month fiscal period is 21.47% and is forecasted to reach -1.90 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 1.07% through the next 5 years, which can be compared against the -46.45% growth it accomplished over the previous five years trading on the market.
In the same vein, IMRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.90, a figure that is expected to reach -0.41 in the next quarter, and analysts are predicting that it will be -1.90 at the market close of one year from today.
Technical Analysis of Immuneering Corp (IMRX)
Going through the that latest performance of [Immuneering Corp, IMRX]. Its last 5-days volume of 1.61 million indicated improvement to the volume of 1.48 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 15.16% While, its Average True Range was 33.26.
Raw Stochastic average of Immuneering Corp (IMRX) in the period of the previous 100 days is set at 46.71%, which indicates a major rise in contrast to 0.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.64 that was higher than 0.52 volatility it exhibited in the past 100-days period.
